There is a need for new sources of multipotent, highly therapeutically effective, patient-specific stem cells. The placenta is a novel potential source of fetal stem cells. Studies of therapeutic use involving placental stem cells have not been conducted. We plan to address this need by accomplishing a research program with support from the NIH that will enable us to develop a therapeutic product utilizing selected placental stromal cells for the treatment of Acute Lung Injury. Acute Lung Injury is a major cause of acute respiratory failure in critically ill patients which requires development of novel modes of therapy This project will further contribute to the advances in knowledge of stem cell function and to the potential for regenerative medicine using stem cells derived from the placenta. Our hypothesis is that the chorion of human placenta contains large numbers of mesenchymal stem cells, which release several beneficial paracrine factors. This hypothesis is based on our recent discoveries that human placenta is a hematopoietic organ and term placenta is a niche of abundant numbers of hematopoietic cells. Other cells, sharing the phenotype of stromal cells and embryonic cells are present in the mesenchyme of human placental chorion. These cells are highly active in paracrine signaling and secrete abundant quantities of growth factors like HGF, KGF, TGF-beta, FGF, GM-CSF, and angiopoietins. Stromal cells from the placenta are effective in restoration of barrier function of injured epithelial layers.
In Specific Aim 1, we will test th multipotency of mesenchymal chorionic cells derived from human placenta and their high paracrine activity. We will generate chorionic mesenchymal cell lines and characterize their proliferation and differentiation potential. Cells will be characterized by their morphology, abiliy to propagate in culture, expression of markers of human embryonic stem cells (SSEA-3, Oct-4, TRA-1-60), and embryoid body formation. We will also measure the paracrine activity of cells by ELISA. Cells for therapy will be selected from 20 placentas upon the levels of secretion of HGF, FGF, TGF-beta, GM-CSF, and angiopoietins.
In Specific Aim 2, we will test the potential therapeutic value of selected placental stromal stem cells for their efficacy in animal and human lung models of acute lung injury. Cells will be tested for treatment of mice with acute lung injury and for development of lung fibrosis. Placental cells will be further investigated for their effectiveness in facilitation of repair of injured lung epithelium and endothelium in an ex vivo perfused human lung preparation. This project will provide abundant, non-controversial and inexpensive source of therapeutically active stromal stem cells, available for use in humans within a very short period of time (2-4 years).
Novel sources of multipotent, highly therapeutically effective patient-specific stem cells are in great need. The placenta is a potential source of fetal stem cells. Few studies involving placental stem cells for therapeutic use have been conducted. We plan to develop a research program, with support from NIH that will enable us to obtain a therapeutic product based upon use of placental stromal cells for the treatment of acute disorders like Acute Lung Injury. Cells will be selected from placentas upon their paracrine activity and tested in animal models of Acute Lung Injury and in isolated ex vivo human lungs. This study will further contribute to the advances in knowledge and to the potential for regenerative medicine using stem cell derived from the placenta. Upon completion, this project will provide novel abundant, non-controversial and inexpensive source of therapeutically active fetal stem cells, available for use in humans within very short period of time, which will determine its outstanding future commercial potential.
|Nazarov, Igor; Lee, Jae W; Soupene, Eric et al. (2012) Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. Stem Cells Transl Med 1:359-72|